Genitourinary Cancers

“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.

“The good news is that we’re getting really good at treating cancer and we have more survivors, but we need to start thinking more carefully about the non-cancer risks following a diagnosis, one of which is cardiovascular disease,” said senior author Ashley Felix, PhD.

"I hope many readers have taken the opportunity to learn from the evolving science and gone back to review the basics of virology, immune response, and clinical trial development to gain a better understanding of this global pathogen," writes Raoul S. Concepcion, MD, FACS.

A nurse practitioner discusses how she supports multiple providers in a large academic practice.

The rates of mental healthcare use were significantly higher for patients versus healthy controls during diagnosis, treatment, and long-term survivorship.

Adam J. Gadzinski, MD, MS, highlights positive outcomes of telemedicine multidisciplinary urologic cancer clinics implemented by the University of Washington/Seattle Cancer Care Alliance.

The data demonstrate how the implementation of a telehealth pathway helped reverse the initial urologic-oncologic outpatient volume decline at an institution during the pandemic.

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.

Among patients with adrenocortical cancer, 60% to 70% relapse after surgery, making novel therapeutics an area of high unmet medical need.

The study also found that among patients with a primary testicular germ cell tumor (TGCT), the incidence of contralateral TGCT increased up to 20 years after initial diagnosis.

The risk was decreased further with each additional chemotherapy cycle a patient received.

"The 21st century has ushered in technology that has created more access and readily available information at our fingertips," Raoul S. Concepcion, MD, FACS.

Urologists and patients show resilience, but we must be better prepared in the future, says urologist R. Jonathan Henderson, MD.

Patients with cancer are particularly susceptible to negative consequences of COVID-19.

A 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.

A standardized, multidisciplinary approach led to similar outcomes based on disease characteristics, not sociodemographic factors.

Median overall survival is the same for both malignancies, study results show.

In this video, Eric Klein, MD, discusses a study evaluating the 17-gene Oncotype DX Genomic Prostate Score assay in African American and Caucasian American men.

The classifier can be a useful adjunct for clinical decision-making, an investigator says.

"In the era of BCG shortage, it would have been highly desirable to demonstrate the efficacy and safety of fewer BCG instillations for high-risk bladder cancer. However, reduced frequency of maintenance BCG instillations is associated with increased risk of cancer recurrence, albeit with fewer adverse effects," writes Badar M. Mian, MD.

The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.

A team-based approach is key to safely and appropriately dispensing checkpoint inhibitors, according to Gautam Jayram, MD.

The FDA has approved 2 poly (ADP-ribose) polymerase (PARP) inhibitors for men with metastatic castration-resistant prostate cancer who have certain genetic mutations, marking the first approvals of this newer drug class in prostate cancer.

Advances in endourology have made kidney-sparing treatments a viable treatment option.

The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.

Results from the phase III TIVO-3 trial of tivozanib (Fotivda) demonstrated a statistically significant improvement in median progression-free survival compared with sorafenib (Sutent), as well as favorable tolerability, in patients with relapsed or refractory renal cell carcinoma.

With additional follow-up of approximately 10 months, monotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) continued to show antitumor activity in men with metastatic castration-resistant prostate cancer. However, monotherapy alone is likely not a sufficient treatment in this patient population, according to Emmanuel Antonarakis, MBBCh, professor of oncology at Johns Hopkins University in Baltimore, Maryland.

Findings from a systematic literature review further our understanding of the prevalence of distinct clinical states of advanced prostate cancer, their association with homologous recombination repair (HRR) gene alterations, and the use of testing methods to identify HRR gene alterations, researchers say.

Misinformation about prostate cancer is rampant online and significantly impacts patient care, study authors said at an American Urological Association press briefing. Researchers using machine learning have taken what they say is a first step to help vet the quality of online content.

In a recent study, researchers examined real-world outcomes for patients with metastatic castration-resistant prostate cancer treated with radium-223 (Xofigo). Study author Rana R. McKay, MD, of UC San Diego Health, discusses this study and its significance in the castration-resistant prostate cancer landscape.